Pimagedine

Drug Profile

Pimagedine

Alternative Names: ALT 11; Aminoguanidine hydrochloride

Latest Information Update: 22 Dec 2003

Price : $50

At a glance

  • Originator Nonindustrial source; Rockefeller University
  • Developer Alteon; Gamida; Nonindustrial source
  • Class Guanidines; Hydrazines; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors; Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Atopic dermatitis; Coronary disorders; Dermatitis; Diabetic complications; Diabetic nephropathies; Stroke; Transplant rejection

Most Recent Events

  • 22 Dec 2003 Discontinued - Preclinical for Stroke (IV)
  • 22 Dec 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 22 Dec 2003 Discontinued - Preclinical for Coronary disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top